GMNN

230,596 patent compounds predicted against GMNN, 184,050 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dequalinium (SCHEMBL34043)	1.00	4/20
Safingol (SCHEMBL6772)	1.00	3/20
Z-Flupentixol (SCHEMBL34200)	0.98	3/20
Safingol (SCHEMBL7651)	0.96	3/20
Phytosphingosine (SCHEMBL20110)	0.78	3/20
SCHEMBL33619	0.57	3/20
SCHEMBL15725	0.54	3/20
Amiloride (SCHEMBL27562)	0.51	3/20
Vinblastine (SCHEMBL3549)	1.00	2/20
Vinblastine (SCHEMBL3550)	1.00	2/20
Vincristine (SCHEMBL3710)	1.00	2/20
Vincristine (SCHEMBL3998)	1.00	2/20
Apomorphine (SCHEMBL8524)	1.00	2/20
Fenretinide (SCHEMBL11703)	1.00	2/20
Fenretinide (SCHEMBL11704)	1.00	2/20
Ouabain (SCHEMBL15433)	1.00	2/20
Fenretinide (SCHEMBL19121)	1.00	2/20
Sphingosine (SCHEMBL19398)	1.00	2/20
Sphingosine (SCHEMBL19399)	1.00	2/20
Danazol (SCHEMBL21107)	1.00	2/20

Clinical trials — most relevant to GMNN by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Valproate and Levocarnitine in Children With Spinal Muscular Atrophy	PHASE3	UNKNOWN
Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease	PHASE2	COMPLETED
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	PHASE2	COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors	PHASE1/PHASE2	UNKNOWN
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria	PHASE2	COMPLETED
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)	PHASE1	COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders	PHASE1	RECRUITING
A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants	PHASE1	RECRUITING
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer	PHASE1	COMPLETED
Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations	EARLY_PHASE1	COMPLETED
Natural History Study of GEMIN-5 Related Neurodevelopmental Disorder	nan	RECRUITING
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS	nan	RECRUITING
Patient-derived Glioma Stem Cell Organoids	nan	ACTIVE_NOT_RECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Hirschsprung Disease Genetic Study	nan	RECRUITING
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)	nan	COMPLETED
Genome Medical Sequencing for Gene Discovery	nan	RECRUITING
Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis	nan	COMPLETED
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development	nan	COMPLETED
Family Blood Pressure Program - GenNet Network	nan	COMPLETED
MNGIE Natural History Study	nan	RECRUITING
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
Improving Genetic Counseling for Patients With Spina Bifida Using Next Generation Sequencing	nan	COMPLETED
Natural History Study of Mitochondrial Myopathy	nan	RECRUITING
Optical and Biochemical Biomarkers in Early Pancreatic Cancer	nan	COMPLETED
Genetic Frontotemporal Dementia Initiative for Neurodevelopment	nan	RECRUITING
Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS)	nan	COMPLETED
CoMPaSS-NMD - Computational Models for New Patients Stratification Strategies of HNMD	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a GMNN binder may also engage these)

Protein	Name	Similarity
O88513	—	1.000	O88513 →
A0JMT0	—	0.996	A0JMT0 →
Q949U2	—	0.994	Q949U2 →
P53150	—	0.994	P53150 →
Q9FY74	—	0.993	Q9FY74 →
Q923W1	—	0.993	Q923W1 →
Q9P7P1	—	0.993	Q9P7P1 →
Q4KLP8	—	0.993	Q4KLP8 →
A7YDW0	—	0.993	A7YDW0 →
Q6AWX6	—	0.993	Q6AWX6 →
Q08DY6	—	0.993	Q08DY6 →
B4GT53	—	0.992	B4GT53 →
Q6KAQ7	—	0.992	Q6KAQ7 →
Q09377	—	0.992	Q09377 →
Q05935	—	0.992	Q05935 →
Q18248	—	0.992	Q18248 →
Q9UPS8	—	0.992	Q9UPS8 →
Q9DB00	—	0.992	Q9DB00 →
F4JZ68	—	0.992	F4JZ68 →
Q5XG48	—	0.991	Q5XG48 →
Q09969	—	0.991	Q09969 →
F4J9Q6	—	0.991	F4J9Q6 →
Q8BHX3	—	0.991	Q8BHX3 →
A8MQG7	—	0.991	A8MQG7 →
Q9Y7X7	—	0.991	Q9Y7X7 →
Q6NTJ3	—	0.990	Q6NTJ3 →
Q52LR7	—	0.990	Q52LR7 →
Q6DD45	—	0.990	Q6DD45 →
Q8LF97	—	0.990	Q8LF97 →
Q0IEW8	—	0.990	Q0IEW8 →